Deinove 2018 Annual Results: a year of significant progress - Nasdaq

Deinove 2018 Annual Results: a year of significant progress  Nasdaq

Finalization of the acquisition of DNV3837, a promising antibiotic for treating severe gastrointestinal infections caused by Clostridium difficile,.